Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT

MEMORANDUM OF UNDERSTANDING WITH WALVAX

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that the Company, has recently entered into a memorandum of understanding (the "**MOU**") with Walvax Biotechnology Co., Ltd. ("**Walvax**") pursuant to which the parties have agreed to bring in their complementary strengths and form a strategic partnership in creating an RNA-centric preventive and precision medicine platform that encompasses joint development, clinical trials and registration as well as sales and distribution. The MOU has a term of two years from and includes the date of signing.

INFORMATION OF WALVAX

Established in 2001, Walvax is a leading high-tech biopharmaceutical enterprise in China. It specializes in vaccines for human use which integrates research and development, production and sales, and its shares are listed on Shenzhen Stock Exchange (stock code: 300142) in 2010. It is a global leader in conventional and novel mRNA vaccines and China's largest exporter, with its products being exported to over 20 countries and regions. It owns four technology platforms comprising "bacterial vaccines, recombinant protein vaccines, mRNA vaccines and recombinant adenoviral vector vaccines" and launched 8 vaccine varieties (with 14 specifications) successfully. Also, its SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5) was approved to be included for emergency use in December 2023, enabling it to become a pioneer of China's vaccine enterprises.

REASONS FOR AND BENEFITS OF THE COLLABORATION UNDER THE MOU

The collaboration under the MOU aligns both the Company's and Walvax's long-term objectives in advancing early detection and preventive medicine to help everyone live a healthy life, signaling an important transition of the Company from early detection to preventive and precision medicine. By bringing together the complementary strengths of the Company and Walvax, the collaboration will create synergies, combining the Company's advanced RNA diagnostic technologies, its proprietary Asian centric disease RNA database, its manufacturing and regulatory capabilities in ASEAN including the region's first industry 4.0 nucleic acid assay and reagent manufacturing plant and local distribution channels in ASEAN, with Walvax's proprietary mRNA vaccine technologies, strong clinical pipeline, and its state-of-the-art vaccine and therapeutics manufacturing infrastructure, thereby creating a synergistic preventive and precision medicine platform spanning research, development and commercial deployment.

SCOPE OF THE COLLABORATION UNDER THE MOU

The collaborative areas as set out in the MOU are as follows:

(a) establish a research center of excellence for RNA-centric preventive and precision medicine in Singapore, to synergize the Company's proprietary disease RNA database and Walvax mRNA technologies to advance research and translation of RNA-centric diagnostics, vaccine and therapeutics;

(b) expedite clinical trials and regulatory approval of existing and clinical pipeline products of diagnostics, vaccines and therapeutics in ASEAN region;

(c) establish a sales and distribution platform in Singapore for existing and pipeline products, focused on serving ASEAN and select international markets; and

(d) establish a supply chain in Singapore to coordinate last mile manufacturing, quality and commercial deployment of existing and pipeline products.

The Board is also of the view that this partnership with Walvax can generate substantial strategic value, which further strengthens the Company's positioning as the anchor for the region's growing RNA diagnostic and therapeutic ecosystem, broadens the Company's product portfolio of early detection and preventive solutions and accelerates the Company's revenue growth. This novel RNA-centric preventive and precision medicine platform will enable global institutions to partner with the Company and Walvax in accessing and advancing regional opportunities, while simultaneously enabling the Company and Walvax strategic access to ASEAN and select international markets. The collaboration is also expected to facilitate cross-border co-investment and collaboration opportunities, enhance corporate visibility, deepen research and development capabilities, and contribute to the Group's long-term growth and revenue diversification.

Shareholders and potential investors of the Company should note that the collaboration under the MOU may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, November 18, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.